Developer docs
API playgroundTry for free, no card

Search company profiles

Chroma Medicine

Full company profile

uuid00008nm

Namestring
Chroma Medicine
Legal namestring
Chroma Medicine, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Chroma Medicine is a clinical-stage biotechnology company developing in vivo genetic medicines based on epigenetic editing — a modality that regulates gene expression by recruiting epigenetic regulators (e.g., DNA methyltransferases, transcriptional activators) to specific genomic loci via a dead Cas9 (dCas9) protein, without cutting or altering the underlying DNA sequence. Its technology stack is modular: lipid nanoparticles (LNPs) deliver cargo to the liver, while engineered virus-like particles (eVLPs / "DLVR particles") extend delivery to extrahepatic tissues, enabling single-dose, programmable, and potentially durable therapeutic interventions. The lead clinical-stage program, CRMA-1001, targets chronic hepatitis B and chronic hepatitis D, indications with high unmet medical need and limited curative treatment options. The company's broader pipeline logic pairs epigenetic cargoes with tissue-targeted delivery to address genetic diseases beyond the liver.

The business model is R&D-driven and pre-commercial: Chroma Medicine monetizes neither approved products nor recurring services. Revenue is "not applicable," and value creation depends on advancing therapeutic programs through preclinical and clinical development, securing regulatory approvals, and ultimately either commercializing directly, out-licensing, or being acquired. Distribution and traditional GTM channels are absent; the company's commercial posture is centered on scientific publication, conference presentation, and partnership development. The company is incorporated in Delaware with operational headquarters in Boston, Massachusetts, and an R&D presence in Milan, Italy, following the 2023 acquisition of Epsilen Bio. In April 2026, Chroma Medicine merged with Nvelop Therapeutics to form nChroma Bio, consolidating scientific and leadership teams and securing an additional $75 million in financing. Across its history, Chroma Medicine has raised approximately $260 million in private equity (a $125M seed in 2021 and a $135M Series B in 2023) from a syndicate including GV, ARCH Venture Partners, Atlas Venture, Cormorant Asset Management, Casdin Capital, Omega Funds, T. Rowe Price, and Wellington Management.

Short descriptiontext

Chroma Medicine (now nChroma Bio) is a clinical-stage biotechnology company developing single-dose, in vivo epigenetic editing therapies that regulate gene expression without cutting DNA, initially targeting chronic hepatitis B and D with lead program CRMA-1001.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
epigenetic editing, genetic medicines, gene regulation, in vivo delivery, targeted therapeutics
Industry1 code
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Genetic Medicines
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Chroma Medicine develops epigenetic editing therapeutics that regulate gene expression without altering DNA sequences, using a platform that fuses epigenetic regulators to dead Cas9 (dCas9) to silence or activate specific genes. The company combines this cargo with modular delivery technologies—LNPs for liver targeting and eVLPs (DLVR particles) for extrahepatic delivery—to develop single-dose, in vivo genetic medicines for diseases of high unmet need. Its lead program CRMA-1001 targets chronic hepatitis B and hepatitis D.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Chroma Medicine was a genomic medicine company (now merged into nChroma Bio) that developed epigenetic editing therapeutics through a modular technology approach. The company's core offerings included an epigenome editing platform that modifies gene expression without DNA alterations, single-dose epigenetic therapeutics, and DLVR particles for extrahepatic delivery using engineered virus-like particles (eVLPs). The lead therapeutic program was CRMA-1001 for chronic hepatitis B and hepatitis D. The company acquired Epsilen Bio (Milan) to strengthen its R&D capabilities. In 2026, Chroma Medicine merged with Nvelop Therapeutics to form nChroma Bio.

Product and service1 record
1CRMA-1001
CategoryTherapeutic Program
Description

Lead epigenetic editing therapy program targeting chronic hepatitis B and chronic hepatitis D infections—diseases of high unmet medical need with limited curative treatment options. Designed as a single-dose, in vivo treatment that regulates gene expression without altering DNA sequences.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest direct competitor: an epigenetic editing company using similar dCas9-effector architecture to durably silence or activate genes without altering DNA sequence, with lead programs in hepatitis B and other chronic diseases.

TypeDirect peer
Description

Closely comparable base-editing platform developing in vivo precision genetic medicines for liver and extrahepatic indications; pursues single-dose durable gene regulation similarly to Chroma's epigenetic editing thesis.

TypeDirect peer
Description

Develops prime editing — a next-generation gene editing modality delivered via viral and non-viral systems targeting liver and extrahepatic tissues; competes with Chroma for both platform positioning and pipeline indications.

TypeDirect peer
Description

Clinical-stage in vivo CRISPR/Cas9 gene editing company using LNPs for liver delivery and other modalities for extrahepatic delivery, directly comparable on delivery architecture and chronic disease strategy.

TypeDirect peer
Description

In vivo base-editing company with a liver-directed portfolio and IND-stage programs; shares Chroma's LNP delivery platform paradigm and chronic disease approach.

TypeBroad incumbent
Description

One of the original CRISPR gene-editing biotechs with a broader portfolio spanning ex vivo and in vivo approaches; broader platform scope but overlapping modality space with Chroma's CRISPR-derived dCas9 platform.

TypeBroad incumbent
Description

Incumbent CRISPR/Cas9 gene editing company with approved Casgevy and pipeline across hemoglobinopathies, oncology and regenerative medicine; broader modality mix with overlapping liver-directed programs.

TypeBroad incumbent
Description

Pioneer in zinc finger and other engineered nuclease platforms for genomic regulation, including epigenetic approaches, with a portfolio spanning rare disease and broader indications.

TypeEmerging player
Description

RNA editing company pursuing oligonucleotide-based, single-dose in vivo gene regulation for liver and other tissues; partial overlap as another non-cutting precision genetic medicines approach.

TypeOthers
Description

While not a gene-editing company, Vir is a leader in chronic hepatitis B and D therapeutics and is highly relevant as a potential competitor and/or partner for CRMA-1001 in its lead indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chroma Medicine

Genetic Medicineschromamedicine.com

Chroma Medicine (now nChroma Bio) is a clinical-stage biotechnology company developing single-dose, in vivo epigenetic editing therapies that regulate gene expression without cutting DNA, initially targeting chronic hepatitis B and D with lead program CRMA-1001.

What Chroma Medicine does

Chroma Medicine is a clinical-stage biotechnology company developing in vivo genetic medicines based on epigenetic editing — a modality that regulates gene expression by recruiting epigenetic regulators (e.g., DNA methyltransferases, transcriptional activators) to specific genomic loci via a dead Cas9 (dCas9) protein, without cutting or altering the underlying DNA sequence. Its technology stack is modular: lipid nanoparticles (LNPs) deliver cargo to the liver, while engineered virus-like particles (eVLPs / "DLVR particles") extend delivery to extrahepatic tissues, enabling single-dose, programmable, and potentially durable therapeutic interventions. The lead clinical-stage program, CRMA-1001, targets chronic hepatitis B and chronic hepatitis D, indications with high unmet medical need and limited curative treatment options. The company's broader pipeline logic pairs epigenetic cargoes with tissue-targeted delivery to address genetic diseases beyond the liver.

The business model is R&D-driven and pre-commercial: Chroma Medicine monetizes neither approved products nor recurring services. Revenue is "not applicable," and value creation depends on advancing therapeutic programs through preclinical and clinical development, securing regulatory approvals, and ultimately either commercializing directly, out-licensing, or being acquired. Distribution and traditional GTM channels are absent; the company's commercial posture is centered on scientific publication, conference presentation, and partnership development. The company is incorporated in Delaware with operational headquarters in Boston, Massachusetts, and an R&D presence in Milan, Italy, following the 2023 acquisition of Epsilen Bio. In April 2026, Chroma Medicine merged with Nvelop Therapeutics to form nChroma Bio, consolidating scientific and leadership teams and securing an additional $75 million in financing. Across its history, Chroma Medicine has raised approximately $260 million in private equity (a $125M seed in 2021 and a $135M Series B in 2023) from a syndicate including GV, ARCH Venture Partners, Atlas Venture, Cormorant Asset Management, Casdin Capital, Omega Funds, T. Rowe Price, and Wellington Management.

Chroma Medicine firmographics

Firmographics
Name
Chroma Medicine
Legal name
Chroma Medicine, Inc.
Website
https://chromamedicine.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
11–50 employees
Short description
Chroma Medicine (now nChroma Bio) is a clinical-stage biotechnology company developing single-dose, in vivo epigenetic editing therapies that regulate gene expression without cutting DNA, initially targeting chronic hepatitis B and D with lead program CRMA-1001.
Ownership category
akta.pro rank

Chroma Medicine industry classification

Industry
Product category
Genetic Medicines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Epigenetic editing
  • Genetic medicines
  • Gene regulation
  • In vivo delivery
  • Targeted therapeutics

Where Chroma Medicine is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Chroma Medicine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Chroma Medicine product offering

Product offering

Core offering

Chroma Medicine develops epigenetic editing therapeutics that regulate gene expression without altering DNA sequences, using a platform that fuses epigenetic regulators to dead Cas9 (dCas9) to silence or activate specific genes. The company combines this cargo with modular delivery technologies—LNPs for liver targeting and eVLPs (DLVR particles) for extrahepatic delivery—to develop single-dose, in vivo genetic medicines for diseases of high unmet need. Its lead program CRMA-1001 targets chronic hepatitis B and hepatitis D.

Product overview

Chroma Medicine was a genomic medicine company (now merged into nChroma Bio) that developed epigenetic editing therapeutics through a modular technology approach. The company's core offerings included an epigenome editing platform that modifies gene expression without DNA alterations, single-dose epigenetic therapeutics, and DLVR particles for extrahepatic delivery using engineered virus-like particles (eVLPs). The lead therapeutic program was CRMA-1001 for chronic hepatitis B and hepatitis D. The company acquired Epsilen Bio (Milan) to strengthen its R&D capabilities. In 2026, Chroma Medicine merged with Nvelop Therapeutics to form nChroma Bio.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRMA-1001 Lead epigenetic editing therapy program targeting chronic hepatitis B and chronic hepatitis D infections—diseases of high unmet medical need with limited curative treatment options. Designed as a single-dose, in vivo treatment that regulates gene expression without altering DNA sequences.

Companies that use Chroma Medicine

Customer profile

Segments1 record

Ideal customer profiles1 record

Chroma Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Chroma Medicine partnerships and signals

Strategic signal

Recent moves8 records

Expansion highlights6 records

Chroma Medicine competitors and assessment

Company assessment

Direct peers

  • Tune Therapeutics: Closest direct competitor: an epigenetic editing company using similar dCas9-effector architecture to durably silence or activate genes without altering DNA sequence, with lead programs in hepatitis B and other chronic diseases.
  • Beam Therapeutics: Closely comparable base-editing platform developing in vivo precision genetic medicines for liver and extrahepatic indications; pursues single-dose durable gene regulation similarly to Chroma's epigenetic editing thesis.
  • Prime Medicine: Develops prime editing — a next-generation gene editing modality delivered via viral and non-viral systems targeting liver and extrahepatic tissues; competes with Chroma for both platform positioning and pipeline indications.
  • Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company using LNPs for liver delivery and other modalities for extrahepatic delivery, directly comparable on delivery architecture and chronic disease strategy.
  • Verve Therapeutics: In vivo base-editing company with a liver-directed portfolio and IND-stage programs; shares Chroma's LNP delivery platform paradigm and chronic disease approach.

Broad incumbents

  • Editas Medicine: One of the original CRISPR gene-editing biotechs with a broader portfolio spanning ex vivo and in vivo approaches; broader platform scope but overlapping modality space with Chroma's CRISPR-derived dCas9 platform.
  • CRISPR Therapeutics: Incumbent CRISPR/Cas9 gene editing company with approved Casgevy and pipeline across hemoglobinopathies, oncology and regenerative medicine; broader modality mix with overlapping liver-directed programs.
  • Sangamo Therapeutics: Pioneer in zinc finger and other engineered nuclease platforms for genomic regulation, including epigenetic approaches, with a portfolio spanning rare disease and broader indications.

Emerging players

  • Korro Bio: RNA editing company pursuing oligonucleotide-based, single-dose in vivo gene regulation for liver and other tissues; partial overlap as another non-cutting precision genetic medicines approach.

Others

  • Vir Biotechnology: While not a gene-editing company, Vir is a leader in chronic hepatitis B and D therapeutics and is highly relevant as a potential competitor and/or partner for CRMA-1001 in its lead indication.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Chroma Medicine social profiles

Digital presence

Chroma Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chroma Medicine leadership team

Management profile

Number of profiles

Profiles7 records

Chroma Medicine subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Chroma Medicine funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chroma Medicine M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chroma Medicine

What does Chroma Medicine do?

Chroma Medicine develops epigenetic editing therapeutics that regulate gene expression without altering DNA sequences, using a platform that fuses epigenetic regulators to dead Cas9 (dCas9) to silence or activate specific genes. The company combines this cargo with modular delivery technologies—LNPs for liver targeting and eVLPs (DLVR particles) for extrahepatic delivery—to develop single-dose, in vivo genetic medicines for diseases of high unmet need. Its lead program CRMA-1001 targets chronic hepatitis B and hepatitis D.

Is Chroma Medicine a public or private company?

Chroma Medicine is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Chroma Medicine founded?

Chroma Medicine was founded in 2021. It employs 11 to 50 people.

Where is Chroma Medicine based?

Chroma Medicine is headquartered in Boston, United States, in the North America region.

Who are Chroma Medicine's main competitors?

Direct peers on record are Tune Therapeutics, Beam Therapeutics, Prime Medicine, Intellia Therapeutics and Verve Therapeutics. Broad incumbents are Editas Medicine, CRISPR Therapeutics and Sangamo Therapeutics. Korro Bio is listed as an emerging player. Vir Biotechnology is listed as an others.

Does Chroma Medicine have an API?

No public API is recorded for Chroma Medicine.

What industry is Chroma Medicine in?

Chroma Medicine's product category is Genetic Medicines. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialHypercholesterolemia Drugs In Development 2026: Pipeline Therapies, Ongoing Trials, And Companies Driving Innovation EPIC BIO, Amytrx Therapeutics, Chroma Medicine, Verve Therapeutics, IncMerck's oral PCSK9 inhibitor Lipfendra received FDA approval in July 2026, reducing LDL-C by 56-59% versus placebo. Other pipeline drugs include Arrowhead's ARO-DIMER-PA and CRISPR's CTX310, with trials ongoing. The report also covers EPIC-221, AMTX 100, and VERVE-102.NchromabioChroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines – nChromaChroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio, a new biotechnology company focused on genetic medicines, with Jeff Walsh appointed CEO and Jeff Marrazzo as Chairman of the Board. The merger was accompanied by an oversubscribed $75 million financing round led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, with participation from additional top-tier investors. The company plans to advance its lead program CRMA-1001, an epigenetic editing therapy for chronic hepatitis B and hepatitis D, with a clinical trial application submission targeted for 2025.BioPharmaTrendChroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio with $75 Million FinancingChroma Medicine and Nvelop Therapeutics merged to form nChroma Bio, a biotech focused on genetic medicines. The company secured $75 million in financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners. The funds will advance its lead program CRMA-1001, a liver-targeted epigenetic editor for hepatitis B and D, toward clinical trials in 2025.Business Wire BlogChroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic MedicinesChroma Medicine and Nvelop Therapeutics merged to form nChroma Bio, led by CEO Jeff Walsh and Chairman Jeff Marrazzo. The company raised $75 million in an oversubscribed financing round to advance its lead candidate CRMA-1001, a liver-targeted epigenetic editor for hepatitis B and D, with a planned clinical trial application in 2025.Business Wire BlogChroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic MedicinesChroma Medicine and Nvelop Therapeutics merged to form nChroma Bio, led by CEO Jeff Walsh and Chairman Jeff Marrazzo. The company raised $75 million in an oversubscribed financing round to advance its lead candidate CRMA-1001 for chronic hepatitis B and D. The funds will support clinical development and pipeline expansion.PR NewswireChroma Medicine Announces Exclusive License Agreement with the Whitehead Institute for Novel Epigenetic Editing TechnologyChroma Medicine announced an exclusive license agreement with the Whitehead Institute to access the novel CHARM epigenetic editing technology developed in the lab of Chroma co-founder Jonathan Weissman, Ph.D. The CHARM technology uses a compact epigenetic editing effector domain to recruit and activate DNA methyltransferases, enabling durable gene silencing without altering the DNA sequence. This agreement expands Chroma's modular epigenetic editing platform as the company works to advance a new class of therapeutics for treating complex diseases.GenengnewsTop Five Privately Held Gene Editing Therapy CompaniesFive privately held gene editing therapy companies are ranked by capital raised, totaling $874 million. Tessera Therapeutics leads with $600 million, followed by Mammoth Biosciences at $465 million. The companies include Arbor, Scribe, and Chroma Medicine.PR NewswireChroma Medicine Announces Appointment of Jenny Marlowe, Ph.D., as Chief Development OfficerChroma Medicine announced the appointment of Jenny Marlowe, Ph.D. as Chief Development Officer. Dr. Marlowe brings extensive experience in genomic medicine from previous roles at Solid Biosciences as Chief Scientific Officer and at bluebird bio, where she served as Program Lead for Zynteglo, an approved gene therapy for beta thalassemia. The company stated the appointment is pivotal as it prepares to transition to clinical development.PR NewswireChroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual MeetingChroma Medicine announced it will present poster data at the 65th ASH Annual Meeting in December 2023 demonstrating its multiplex epigenetic editing platform's potential to produce functional allogeneic CAR T cells without graft-versus-host-disease response. The data shows these engineered cells can resist T cell alloresponses and NK missing-self response without introducing genotoxic events or chromosomal rearrangements. The poster will be presented by Associate Director Jamie Schafer on December 10, 2023, in San Diego, California.PR NewswireChroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of DirectorsChroma Medicine, a biotechnology company pioneering epigenetic editing therapeutics, has appointed Michael A. Kelly to its Board of Directors. Kelly brings decades of strategic finance and business operations experience, having previously served as Senior Vice President at Amgen and founded Sentry Hill Partners in 2018. The appointment is intended to strengthen Chroma's leadership as it advances its single-dose epigenetic editing platform for treating serious diseases.